Dr. Steven Weisbord is an Associate Professor of Medicine and Clinical and Translational Science in the Renal-Electrolyte Division at the University of Pittsburgh and a Staff Nephrologist at the VA Pittsburgh Healthcare System. He is also an Associate Investigator at the Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System. His main research interests include processes of care related to acute kidney injury and quality of life and symptom burden in maintenance hemodialysis patients. He was the Principal Investigator and Study Chairman of the ‘PRESERVE’ study, a VA Cooperative Studies Program sponsored multi-national, randomized clinical trial that compared interventions for the prevention of serious adverse outcomes related to contrast-induced acute kidney injury. The results of the PRESERVE trial, which enrolled over 5,000 patients, were published in the New England Journal of Medicine in 2018. Dr. Weisbord is also co-Principal Investigator of a National Institutes of Health sponsored study that is ancillary to the PRESERVE trial that established a biorepository of blood and urine samples of trial participants. This biobank is being used to identify blood and urine biomarkers for the stratification of risk for and diagnosis of the incipient stages of contrast-induced acute kidney injury. Dr. Weisbord also served as the Principal Investigator of the SMILE study, a multicenter clinical trial that compared two strategies for the management of symptoms in patients receiving chronic hemodialysis.